Evdoxia Kyriazopoulou

Evdoxia, MD, MSc, PhD is an Intensivist in the 2nd Department of Critical Care Medicine, University of Athens. She was born and studied Medicine in Athens, Greece. She was trained in Internal Medicine in Heilbronn, Germany (2011-2013) and finished her clinical training in the 4th Department of Internal Medicine, University of Athens (2014-2016).

She received a PhD in biomarker-guided treatment in sepsis from the same University in 2020. Her postdoctoral research (2022-2024) focused on immune dysregulation of long covid syndrome. Her main research interests are the immunology of sepsis, sepsis biomarkers, immunomodulation in sepsis, and COVID-19.

She was awarded the first prize “Sotirios Papastamatis” in 2016 for her research on Macrophage Activation-like Syndrome in sepsis. She was the main investigator of the SAVE and SAVE-MORE clinical trials, the results of which led to the authorization approval of anakinra for COVID-19 by the European Medicines Agency.

She is a board member of the Hellenic Society of Chemotherapy and a member of the Hellenic Sepsis Study Group, the European Society of Clinical Microbiology and Infectious Diseases, and the International Society of Antimicrobial Chemotherapy Early Career Working Group.